

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441606-00021	Date of first issue: 06.01.2016

#### **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier Trade name	Orbifloxacin / Posaconazole / M	ometasone Formulation
1.2 Relevant identified uses of	substance or mixture and uses	advised against
Use of the Sub- stance/Mixture	Veterinary product	
Recommended restrictions on use	Not applicable	
1.3 Details of the supplier of th	fety data sheet	
Company	MSD Kilsheelan Clonmel Tipperary, IE	
Telephone	353-51-601000	
E-mail address of person responsible for the SDS	EHSDATASTEWARD@msd.com	n

### 1.4 Emergency telephone number

+1-908-423-6000

## **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Long-term (chronic) aquatic hazard, Cat-	H411: Toxic to aquatic life with long lasting effects.
egory 2	

#### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H319 Causes serious eye irritation.



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
		H411 Toxic to	aquatic life with long lasting effects.
Preca	utionary statements	P273 Avoid rel	in thoroughly after handling. lease to the environment. e protection/ face protection.
		<b>Response:</b> P337 + P313 I attention. P391 Collect s	f eye irritation persists: Get medical advice/ pillage.

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 1 - < 3
Posaconazole	171228-49-2	Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Adrenal gland, Bone marrow, Kid- ney, Liver, Nervous system, Reproduc- tive organs) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 0,1 - < 0,25

## SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Orbifloxacin / Posaconazole / Mometasone Formulation

		SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016			
Mome	etasone	83919-23-7	M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) 			

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

4.1 Description of first aid measures						
General advice :		In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.				
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).				
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.				
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.				
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.				
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.				



Version 2.19	Revision Date: 28.09.2024		9S Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016			
4.2 Most important symptoms ar Risks			d effects, both acute and delayed : Causes serious eye irritation.				
	ation of any immediate atment	mec :	nedical attention and special treatment needed : Treat symptomatically and supportively.				
SECTIO	N 5: Firefighting meas	sur	es				
5.1 Extin	guishing media						
Suita	able extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide ( Dry chemical				
	Unsuitable extinguishing media		None known.				
5.2 Spec	ial hazards arising from	the	e substance or mi	xture			
Spe fight		:	Exposure to com	bustion products may be a hazard to health.			
Hazardous combustion prod- ucts		:	Carbon oxides				
5.3 Advi	ce for firefighters						
	cial protective equipment refighters	:		e, wear self-contained breathing apparatus. tective equipment.			
Specific extinguishing meth- ods		:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do			

## 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).

## 6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment.
		Prevent further leakage or spillage if safe to do so.
		Prevent spreading over a wide area (e.g. by containment or oil



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
			bose of contaminated wash water. es should be advised if significant spillages ained.
6.3 Method	is and material for co	ontainment and clea	ning up
6.3 Methods and material for contain Methods for cleaning up :		For large spills, ment to keep m be pumped, sto Clean up remain bent. Local or national posal of this ma employed in the mine which reg Sections 13 an	hert absorbent material. , provide dyking or other appropriate contain- haterial from spreading. If dyked material can bre recovered material in appropriate container. ining materials from spill with suitable absor- al regulations may apply to releases and dis- aterial, as well as those materials and items e cleanup of releases. You will need to deter- julations are applicable. d 15 of this SDS provide information regarding national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	<ul> <li>Do not get on skin or clothing.</li> <li>Do not breathe vapours or spray mist.</li> <li>Do not swallow.</li> <li>Do not get in eyes.</li> <li>Wash skin thoroughly after handling.</li> <li>Handle in accordance with good industrial hygiene and safety</li> </ul>
	practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	<ul> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use.</li> <li>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</li> </ul>



VersionRevision Date:SDS Number:Date of last issue: 06.04.20242.1928.09.2024441606-00021Date of first issue: 06.01.2016					
---	--	--	--	--	--

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	:	Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases
7.3 Specific end use(s)		

## Specific use(s)

: No data available

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
White mineral oil (petroleum)	8042-47-5	TWA (Vapour)	50 mg/m3	FOR-2011- 12-06-1358
		TWA (Mist and particles)	1 mg/m3	FOR-2011- 12-06-1358
Orbifloxacin	113617-63- 3	TWA	0.2 mg/m3 (OEB 2)	Internal
Posaconazole	171228-49- 2	TWA	300 µg/m3 (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	nation: Skin	· · · · ·	
		Wipe limit	10 µg/100 cm²	Internal

#### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

:

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

#### Personal protective equipment

Eye/face protection

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Hand	protection		shield or other full face protection if there is a direct contact to the face with dusts, mists, or
Ma	aterial	: Chemical-res	istant gloves
	marks and body protection	Additional bo being perforn suits) to avoid	n or laboratory coat. dy garments should be used based upon the task ned (e.g., sleevelets, apron, gauntlets, disposable d exposed skin surfaces. ate degowning techniques to remove potentially
	ratory protection ter type	sure assessn ommended g Equipment sl	bcal exhaust ventilation is not available or expo- ment demonstrates exposures outside the rec- uidelines, use respiratory protection. mould conform to NS EN 14387 articulates and organic vapour type (A-P)

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state	:	suspension
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available

Commission Regulation (EU) 2020/878



## **Orbifloxacin / Posaconazole / Mometasone** Formulation

Vers 2.19		Revision Date: 28.09.2024		S Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
	Decom	position temperature	:	No data available	e
	рН		:	No data available	e
	Viscos Vise	ity cosity, kinematic	:	No data available	e
		lity(ies) ter solubility	:	No data available	e
		on coefficient: n- I/water	:	Not applicable	
	Vapou	r pressure	:	No data available	9
	Relativ	e density	:	No data available	e
	Densit	у	:	No data available	e
	Relativ	ve vapour density	:	No data availabl	e
		e characteristics ticle size	:	Not applicable	
9.2	Other i	nformation			
	Explos	ives	:	Not explosive	
	Oxidizi	ing properties	:	The substance of	r mixture is not classified as oxidizing.
	Evapo	ration rate	:	No data availabl	e

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials



Version 2.19	Revision Date: 28.09.2024		9S Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Mate	rials to avoid	:	Oxidizing agents	
	rdous decomposition pazardous decomposition			
SECTION	N 11: Toxicological in	for	mation	
11.1 Infor	mation on hazard class	ses	as defined in Reg	ulation (EC) No 1272/2008
Inforr expos	nation on likely routes of sure	:	Inhalation Skin contact Ingestion Eye contact	
Acut	e toxicity			
	lassified based on availa	ble	information.	
Prod				
Acute	e oral toxicity	:	LD50 (Rat): > 2.00 Remarks: No sign No mortality obser	ificant adverse effects were reported
Acute	e dermal toxicity	:	LD50 (Rat): > 2.00 Remarks: No sign	00 mg/kg ificant adverse effects were reported
Com	ponents:			
Orbif	loxacin:			
Acute	e oral toxicity	:	LD50 (Rat): > 3.00 Remarks: No mor	00 mg/kg tality observed at this dose.
			LD50 (Mouse): > 2 Remarks: No mor	2.000 mg/kg tality observed at this dose.
			LD50 (Dog): > 600 Symptoms: Vomit Remarks: No mor	
Acute	inhalation toxicity	:	Remarks: No data	a available
Acute	e dermal toxicity	:	Remarks: No data	a available
	e toxicity (other routes of nistration)	:	LD50 (Rat): > 200 Application Route	
			LD50 (Mouse): 50 Application Route	
			LD50 (Rat): 233 m Application Route	



19	Revision Date: 28.09.2024		S Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
			LD50 (Mouse): 2 Application Rout	
Posad	conazole:			
Acute	oral toxicity	:	LD50 (Rat): > 5.0	000 mg/kg
			LD50 (Mouse): >	3.000 mg/kg
Acute	dermal toxicity	:	LD50 (Rat): > 2.0	000 mg/kg
Mome	etasone:			
Acute	oral toxicity	:	LD50 (Rat): > 2.0	000 mg/kg
			LD50 (Mouse): >	2.000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 3, Exposure time: 4 Test atmosphere Remarks: No mo	h
			LC50 (Mouse): > Exposure time: 4 Test atmosphere	h
	toxicity (other routes of istration)	:		e: Subcutaneous
Skin o	corrosion/irritation			
-	corrosion/irritation assified based on availa	ble	information.	
Not cl <u>Produ</u>	assified based on availa <u>Ict:</u>	ble		
Not cl	assified based on availa <u>Ict:</u> es	ble :	information. Rabbit Mild skin irritation	ı
Not cla Produ Specie Resul	assified based on availa <u>Ict:</u> es	ble : :	Rabbit	1
Not cli Produ Specie Result	assified based on availa <u>Ict:</u> es t	ble : :	Rabbit	ı
Not cli Produ Specie Result	assified based on availa act: es t bonents: oxacin:	ble : :	Rabbit	ſ
Not cla Produ Specie Result Comp Orbifl Specie Metho	assified based on availa <u>act:</u> es t bonents: oxacin: es od	ble : :	Rabbit Mild skin irritation Rabbit Draize Test	l
Not cla Produ Specia Result Comp Orbifl Specia	assified based on availa <u>act:</u> es t bonents: oxacin: es od	ble : :	Rabbit Mild skin irritation Rabbit	l
Not cla Produ Specia Result Comp Orbifl Specia Metho Result	assified based on availa <u>act:</u> es t bonents: oxacin: es od	ble : :	Rabbit Mild skin irritation Rabbit Draize Test	ı
Not cli Produ Specia Result Comp Orbifl Specia Result Posac Specia	assified based on availa <u>act:</u> es t <b>conents:</b> <b>oxacin:</b> es od t <b>conazole:</b> es	ble : : :	Rabbit Mild skin irritation Rabbit Draize Test No skin irritation Rabbit	l
Not cli Produ Specia Result Comp OrbifI Specia Result Posad	assified based on availa <u>act:</u> es t <b>conents:</b> <b>oxacin:</b> es od t <b>conazole:</b> es	ble : : :	Rabbit Mild skin irritation Rabbit Draize Test No skin irritation	١
Not cli Produ Specia Result Orbifl Specia Result Posac Specia Result	assified based on availa <u>act:</u> es t <b>conents:</b> <b>oxacin:</b> es od t <b>conazole:</b> es	ble : : :	Rabbit Mild skin irritation Rabbit Draize Test No skin irritation Rabbit	1



ersion 19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016				
Result		: No skin irri	: No skin irritation				
	us eye damage/eye es serious eye irritatio						
Produ	uct:						
Speci Resul	es	: Rabbit : Mild eye in	itation				
Comr	oonents:						
	oxacin:						
Speci		: Rabbit					
Metho		: Draize Tes	t				
Resul		: Mild eye ir					
	conazole:						
Speci Resul		: Rabbit	itation				
Resul	L	: Mild eye ir	nation				
	etasone:	Dalla					
Speci Resul		: Rabbit : No eye irri	ation				
Respi	ratory or skin sensi	tisation					
-	ratory or skin sensi	tisation					
Skin s	sensitisation						
Skin s Not cl	sensitisation assified based on ava	ailable information					
Skin s Not cl Respi	sensitisation assified based on avainatory sensitisation	ailable information					
Skin s Not cl Respi Not cl	sensitisation assified based on avainatory sensitisation assified based on avai	ailable information					
Skin s Not cl Respi Not cl <u>Produ</u>	sensitisation assified based on avainatory sensitisation assified based on avaination	ailable information					
Skin s Not cl Respi Not cl <u>Produ</u> Test T	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory	ailable information					
Skin s Not cl Respi Not cl <u>Produ</u> Test T	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory act: Type sure routes	ailable information ailable information : Magnusso	n-Kligman-Test				
Skin s Not cl Respi Not cl <u>Produ</u> Test T Expos Resul	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory act: Type sure routes	ailable information ailable information : Magnusso : Dermal	n-Kligman-Test				
Skin s Not cl Respi Not cl <u>Produ</u> Test T Expos Resul	sensitisation assified based on avainatory sensitisation assified based on avainator assified based on avainator act: Type sure routes t	ailable information ailable information : Magnusso : Dermal	n-Kligman-Test				
Skin s Not cl Respi Not cl Produ Test T Expos Resul Comp Orbifl Test T	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory act: Type sure routes t ponents: oxacin: Type	ailable information ailable information : Magnusso : Dermal : Not a skin : Maximisati	n-Kligman-Test sensitizer.				
Skin s Not cl Respi Not cl Produ Test T Expos Resul Comp Orbifl Test T Expos	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory astronometes toponents: oxacin: Type sure routes	ailable information ailable information : Magnusso : Dermal : Not a skin : Maximisati : Dermal	n-Kligman-Test sensitizer. on Test				
Skin s Not cl Respi Not cl Produ Test T Expos Resul Comp Orbifl Test T	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory astronatory bype sure routes t oxacin: Type sure routes es	ailable information ailable information : Magnusso : Dermal : Not a skin : Maximisati	n-Kligman-Test sensitizer. on Test				
Skin s Not cl Respi Not cl Produ Test T Expos Resul Orbifl Test T Expos Speci Resul	sensitisation assified based on avainatory sensitisation assified based on avainatory assified based on avainatory astronatory bype sure routes t oxacin: Type sure routes es	ailable information ailable information : Magnusso : Dermal : Not a skin : Dermal : Dermal : Guinea pig	n-Kligman-Test sensitizer. on Test				
Skin s Not cl Respi Not cl Produ Test T Expos Resul Orbifl Test T Expos Speci Resul	sensitisation assified based on availation assified based on availation as	ailable information ailable information : Magnusso : Dermal : Not a skin : Dermal : Guinea pig : Not a skin	n-Kligman-Test sensitizer. on Test				



Version 2.19	Revision Date: 28.09.2024	SDS Nur 441606-0		Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Spec Resu		: Guin : nega	ea pig tive	
Test Expo Spec	sure routes ies ssment It	: Derm : Guin : Does : nega : The i	ea pig s not cause s tive	skin sensitisation. est on guinea pigs showed this substance to
	n cell mutagenicity lassified based on ava	ilable inform	nation.	
Com	ponents:			
	iloxacin: otoxicity in vitro		Type: Bacte ılt: equivoca	rial reverse mutation assay (AMES)
			Type: Mous ılt: positive	e Lymphoma
		Test		nosomal aberration nan lymphocytes
Geno	otoxicity in vivo	Spec Cell t Appli	ties: Mouse type: Bone n	nucleus test narrow e: Intraperitoneal injection
		Spec Cell t Appli	Type: unsch cies: Rat type: Liver c ication Route ilt: negative	
Germ sessr	n cell mutagenicity- As- ment		ht of eviden nutagen.	ce does not support classification as a germ
Posa	conazole:			
	otoxicity in vitro		Type: Bacte Ilt: negative	rial reverse mutation assay (AMES)
			Type: Chror Ilt: negative	nosomal aberration



sion 9	Revision Date: 28.09.2024		S Number: 606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Geno	toxicity in vivo		Test Type: Micro Species: Mouse Cell type: Bone r Application Route Result: negative	narrow
Mome	etasone:			
Genotoxicity in vitro			Test Type: Bacte Result: negative	rial reverse mutation assay (AMES)
			••	nosomal aberration nese hamster lung cells
				nosomal aberration nese hamster ovary cells
			Test Type: Mous Result: negative	e Lymphoma
Genotoxicity in vivo			Test Type: Micro Species: Mouse Application Route Result: negative	
			Test Type: Chror Species: Rat Cell type: Bone r Result: negative	nosomal aberration narrow
			Test Type: unsch Species: Rat Cell type: Liver c Result: negative	neduled DNA synthesis assay ells
Germ sessn	cell mutagenicity- As- nent		Weight of eviden cell mutagen.	ce does not support classification as a gerr
	nogenicity assified based on availa	able ii	nformation.	
<u>Comp</u>	oonents:			
Orbif	oxacin:			
	cation Route sure time EL	:	Rat Oral 2 Years 200 mg/kg body	weight

: negative

Result



Version 2.19	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.2024441606-00021Date of first issue: 06.01.2016				
	cation Route sure time EL	: Mouse : Oral : 2 Years : 200 mg/kg body weight : negative				
Posa	conazole:					
	cation Route sure time It	<ul> <li>Rat</li> <li>oral (feed)</li> <li>2 Years</li> <li>positive</li> <li>The mechanism or mode of action is not relevant in humans</li> </ul>	6.			
	cation Route sure time It	<ul> <li>Mouse</li> <li>Oral</li> <li>2 Years</li> <li>positive</li> <li>The mechanism or mode of action is not relevant in humans</li> </ul>				
Mom	etasone:					
	cation Route sure time	<ul> <li>Rat</li> <li>Inhalation</li> <li>2 Years</li> <li>0.067 mg/kg body weight</li> <li>negative</li> </ul>				
	cation Route sure time	<ul> <li>Mouse</li> <li>Inhalation</li> <li>19 Months</li> <li>0.160 mg/kg body weight</li> <li>negative</li> </ul>				
-	oductive toxicity					
	lassified based on avai	ble information.				
	oonents:					
	<b>loxacin:</b> is on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects				
Effect ment	s on foetal develop-	<ul> <li>Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight</li> </ul>				



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
			atogenic effects, Embryotoxic effects and ad- on the offspring were detected only at high ma- doses
		Species: Rabl Application Ro General Toxic Embryo-foetal Result: No eff toxic effects a	bute: Oral hity Maternal: NOAEL: 20 mg/kg body weight toxicity: NOAEL: 60 mg/kg body weight ects on early embryonic development, Embryo- nd adverse effects on the offspring were detect- n maternally toxic doses, Reduced maternal
•	roductive toxicity - As- ment	: Some evidend animal experi	e of adverse effects on development, based on ments.
Pos	aconazole:		
Effe	cts on fertility	Species: Rat, General Toxic	ity - Parent: NOAEL: 180 mg/kg body weight o effects on mating performance
		Species: Rat, General Toxic	ity - Parent: NOAEL: 45 mg/kg body weight o effects on mating performance
Effe men	cts on foetal develop- t	Species: Rat, Application Ro Developmenta	
		Species: Rabl	al Toxicity: LOAEL: 40 mg/kg body weight
•	roductive toxicity - As- ment	: Some evidend animal experi	e of adverse effects on development, based on ments.



Versior 2.19	n Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016			
Мо	ometasone:					
Effects on fertility		Fertility: NOAl Symptoms: Ro weight	rtility oute: Subcutaneous EL: 0,015 mg/kg body weight educed embryonic survival, Reduced foetal ects on fertility, Effect on reproduction capacity			
Effects on foetal develop- ment		Species: Mou Application Ro Embryo-foetal	nbryo-foetal development se bute: Subcutaneous toxicity: LOAEL: 0,06 mg/kg body weight rotoxic effects., Teratogenicity and developmen-			
		Species: Rat Application Ro Embryo-foetal	nbryo-foetal development oute: Dermal toxicity: LOAEL: 0,3 mg/kg body weight ro-foetal toxicity			
		Species: Rabl Application Ro Embryo-foetal				
		Species: Rat Application Ro	nbryo-foetal development oute: Subcutaneous toxicity: LOAEL: 0,15 mg/kg body weight s on newborn			
		Species: Rabl Application Ro Embryo-foetal				
	eproductive toxicity - As- ssment	animal experir	Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.			

#### STOT - single exposure

Not classified based on available information.

#### **Components:**

#### Mometasone:

Remarks

: Based on available data, the classification criteria are not met.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441606-00021	Date of first issue: 06.01.2016

#### STOT - repeated exposure

Not classified based on available information.

#### Components:

<b>Posaconazole:</b> Exposure routes Target Organs Assessment	:	Ingestion Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system Causes damage to organs through prolonged or repeated exposure.
Mometasone: Exposure routes Target Organs Assessment	:	inhalation (dust/mist/fume) Immune system, Liver, Kidney, Skin May cause damage to organs through prolonged or repeated exposure.
Repeated dose toxicity		
Components:		
Orbifloxacin: Species NOAEL LOAEL Application Route Exposure time Target Organs	: :	Rat 20 mg/kg 80 mg/kg Oral 3 Months Testis, Liver, Kidney, spleen
Species NOAEL LOAEL Application Route Exposure time	:	Mouse 80 mg/kg 250 mg/kg Oral 3 Months

Species : Juvenile dog NOAEL 50 mg/kg : LOAEL 250 mg/kg : Application Route : Oral Exposure time 14 Days : Target Organs Heart, Bone : Symptoms Gastrointestinal disturbance : Remarks mortality observed : Species Juvenile dog : NOAEL 2 mg/kg : LOAEL : 3 mg/kg : **Application Route** Oral



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016			
Targ	osure time let Organs larks	: 90 Days : Bone : No significant	adverse effects were reported			
Species NOAEL Application Route Exposure time		: Dog : 37,5 mg/kg : Oral : 30 Days	: 37,5 mg/kg : Oral			
Species NOAEL LOAEL Application Route Exposure time Symptoms		: Cat : 7,5 mg/kg : 22,5 mg/kg : Oral : 1 Months : Gastrointestir	: 7,5 mg/kg : 22,5 mg/kg : Oral			
Spec LOA Appl Expo		: Rat, female : 5 mg/kg : Oral : 6 Months : Adrenal gland	l, Lungs, Heart, Liver, spleen, Kidney, Ovary			
Expo		: Dog : 3 mg/kg : Oral : 392 Days : Lungs, Liver, cord, lymphoi	Brain, small intestine, Adrenal gland, Spinal d tissue			
Expo		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrow	, Adrenal gland, Lymph nodes, Blood			
Expo			l, Bone marrow, Kidney, Nervous system, ıs gland, Testis, lymphoid tissue			
Expo		: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gastro	intestinal tract, spleen			
Spec LOA		: Monkey : 8 mg/kg				



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Application Route Exposure time Target Organs		: Intravenous : 1 Months : Cardio-vase	cular system, Lungs, Adrenal gland, Blood
Mometasone: Species NOAEL LOAEL Application Route Exposure time Target Organs		<ul> <li>Rat</li> <li>0,005 mg/kg</li> <li>0,3 mg/kg</li> <li>Oral</li> <li>30 d</li> <li>Lymph nodes, Liver, Adrenal gland, Skin, thymus gland</li> </ul>	
Expo		: Dog : 0,5 mg/kg : Oral : 30 d : Lymph nod	es, Liver, Adrenal gland, Skin, thymus gland
Expo		: 90 d : Adrenal gla	g/l dust/mist/fume) nd, Lungs, Lymph nodes, spleen, Bone marrow, er, thymus gland
Species NOAEL Application Route Exposure time Target Organs		: 90 d : Adrenal gla	l dust/mist/fume) nd, Lungs, Lymph nodes, spleen, Bone marrow, mus gland, Liver

#### Aspiration toxicity

Not classified based on available information.

#### **Components:**

#### Mometasone:

Not applicable

#### 11.2 Information on other hazards

#### Endocrine disrupting properties

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441606-00021	Date of first issue: 06.01.2016

#### Experience with human exposure

Components:		
Orbifloxacin:		
Ingestion	:	Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.
Posaconazole:		
Ingestion	:	Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance
Mometasone:		
Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper res- piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching
Further information		
Components:		
Mometasone:		
Remarks	:	Dermal absorption possible

### **SECTION 12: Ecological information**

### 12.1 Toxicity

#### Components:

### Posaconazole:

Toxicity to fish :	LC50 (Oncorhynchus mykiss (rainbow trout)): > 0,95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	EC50 (Daphnia magna (Water flea)): 0,276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic : plants	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 0,041 mg/l



Versio 2.19	on	Revision Date: 28.09.2024		0S Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016	
				Exposure time: 72 Method: OECD T		
	M-Facto city)	or (Acute aquatic tox-	:	1		
ſ	Toxicity to microorganisms		:	EC50 (Natural microorganism): > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209		
	Toxicity to fish (Chronic tox- icity)		:	NOEC: 0,206 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210		
a	Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)		:	NOEC: 0,244 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility		
	M-Factor (Chronic aquatic toxicity)		:	1		
ſ	Mometa	asone:				
٦	Toxicity	to fish	:	Exposure time: 96	eryllina (Silverside)): 0,11 mg/l 5 h city at the limit of solubility	
				Exposure time: 7	n variegatus (sheepshead minnow)): > 5 mg/l d city at the limit of solubility	
		to daphnia and other invertebrates	:	Exposure time: 48 Method: OECD T		
	Toxicity plants	to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD T		
F	Toxicity	to microorganisms	:	EC50 : > 1.000 m Exposure time: 3		

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Orbifloxacin / Posaconazole / Mometasone Formulation

Versio 2.19	Version Revision Date: 2.19 28.09.2024			DS Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016	
					ration inhibition est Guideline 209 icity at the limit of solubility	
					h	
	Toxicity to fish (Chronic tox- icity)		:	NOEC: 0,00014 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210		
а	Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)		:	Method: OECD T		
	M-Fact	or (Chronic aquatic	:	100		
	•	, tence and degradabil	ity			
<u>c</u>	Compo	onents:				
F	Posaco	onazole:				
E	Biodeg	radability	:	Result: Not readil Biodegradation: Exposure time: 24 Method: OECD T	50 %	
S	Stability	y in water	:		life (DT50): > 30 d est Guideline 111	
Ν	Momet	asone:				
		radability	:	Result: Not readil Biodegradation: Exposure time: 2 Method: OECD T	50 %	
S	Stability	y in water	:	Hydrolysis: 50 % Method: OECD T	(12 d) est Guideline 111	
12.3 E	12.3 Bioaccumulative potential					
C	Compo	onents:				

Components:

Posaconazole:



Vers 2.19		Revision Date: 28.09.2024		DS Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
	Bioaccumulation		:	Bioconcentration	s macrochirus (Bluegill sunfish) factor (BCF): 20 est Guideline 305
	Partitic octano	n coefficient: n- I/water	:	log Pow: 4,15	
	Mome	tasone:			
	Bioacc	umulation	:	Bioconcentration	s macrochirus (Bluegill sunfish) factor (BCF): 107,1 est Guideline 305
	Partitic octano	n coefficient: n- I/water	:	log Pow: 4,68	
12.4	Mobili	ty in soil			
	Comp	onents:			
	Posac	onazole:			
	Distribution among environ- mental compartments		:	log Koc: 5,52	
	Mometasone:				
		ution among environ- compartments	:	log Koc: 4,02	
12.5	Result	ts of PBT and vPvB a	sse	ssment	
	Produ	ct:			
	Assess		:	to be either persis	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Endocrine disrupting prope		ertie	es		
	<u>Produ</u>				
	Assess	sment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.

### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods



Version 2.19	Revision Date: 28.09.2024	SDS Number: 441606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
Product		<ul> <li>Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Co are not product specific, but application specific. Waste codes should be assigned by the user, preferably discussion with the waste disposal authorities. Do not dispose of waste into sewer.</li> </ul>	
Contaminated packaging		dling site for rec	rs should be taken to an approved waste han- cycling or disposal. specified: Dispose of as unused product.

### **SECTION 14: Transport information**

### 14.1 UN number or ID number

	ADN	:	: UN 3082		
	ADR	:	UN 3082		
	RID	:	UN 3082		
	IMDG	:	UN 3082		
	ΙΑΤΑ	:	UN 3082		
14.	2 UN proper shipping name				
	ADN	:	ENVIRONMENTALL` N.O.S. (Mometasone, Posac	Y HAZARDOUS SUBSTANCE, LIQUID,	
	ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID N.O.S. (Mometasone, Posaconazole)		
	RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)		
	IMDG	:	<ul> <li>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)</li> </ul>		
	ΙΑΤΑ	:	Environmentally haza (Mometasone, Posac	ardous substance, liquid, n.o.s. conazole)	
14.	3 Transport hazard class(es)				
			Class	Subsidiary risks	
	ADN	:	9		
	ADR	:	9		
	RID	:	9		
	IMDG	:	9		
	ΙΑΤΑ	:	9		
14.	4 Packing group				



Vers 2.19		Revision Date: 28.09.2024		OS Number: 1606-00021	Date of last issue: 06.04.2024 Date of first issue: 06.01.2016
		g group cation Code Identification Number		III M6 90 9	
	Hazard Labels	g group cation Code Identification Number restriction code	:	III M6 90 9 (-)	
		g group cation Code Identification Number	:	III M6 90 9	
	IMDG Packing Labels EmS C		:	III 9 F-A, S-F	
	aircraft	g instruction (cargo g instruction (LQ)	:	964 Y964 III Miscellaneous	
	IATA (F Packing ger airc	g instruction (LQ)	:	964 Y964 III Miscellaneous	
14.5	5 Enviro	nmental hazards			
	ADN Enviror ADR	mentally hazardous	:	yes	
	RID	mentally hazardous	:	yes yes	
	<b>IMDG</b> Marine	pollutant	:	yes	
		Passenger) Imentally hazardous	:	yes	
	<b>IATA ((</b> Enviror	Cargo) Imentally hazardous	:	yes	



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441606-00021	Date of first issue: 06.01.2016

#### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

## **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parlian major-accident hazards involving dangerous substances.		t and of the Council on the control of

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL HAZARDS	200 t	500 t

# The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441606-00021	Date of first issue: 06.01.2016

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H319	:	Causes serious eye irritation.
H360Df	:	May damage the unborn child. Suspected of damaging fertili-
		ty.
H361d	:	Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.
H373	:	May cause damage to organs through prolonged or repeated exposure if inhaled.
H400		Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.
11410	•	very toxic to aqualic life with forg lasting effects.
Full text of other abbreviatio	ns	
Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Eye Irrit.		Eye irritation

Eye Irrit.	: Eye irritation
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
FOR-2011-12-06-1358	: Norway. Occupational Exposure limits
FOR-2011-12-06-1358 /	: Long term exposure limit
TWA	<b>-</b> .

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified;



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.19	28.09.2024	441606-00021	Date of first issue: 06.01.2016

NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### Further information

Sources of key data use compile the Safety Data Sheet	eChem Por	nnical data, data from raw material SDSs, OECD al search results and European Chemicals Agen- ha.europa.eu/
Classification of the mixture:		Classification procedure:
Eye Irrit. 2	H319	Based on product data or assessment
Aquatic Chronic 2	H411	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN